Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Sun Pharmaceutical Industries Business Update

Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.

Source

BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Sun Pharmaceutical Industries Ltd: key numbers

Share price
₹1,757.50
Market cap
₹4,21,683 Cr
Revenue (annual)
₹58,462 Cr
Net profit (annual)
₹11,479 Cr
P/E (TTM)
34.9×Sector 46.5×
Promoter holding
52.68%-1.80% QoQ
FII holding
14.36%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Sun Pharmaceutical Industries Ltd

All →

Other business update announcements

All →